14:28:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-20 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning VIVE 0.00 SEK
2024-05-23 Kvartalsrapport 2024-Q1
2024-05-23 Årsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning VIVE 0.00 SEK
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning VIVE 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-25 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning VIVE 0.00 SEK
2021-05-25 Kvartalsrapport 2021-Q1
2020-09-10 Ordinarie utdelning VIVE 0.00 SEK
2020-09-09 Årsstämma 2021
2020-06-18 Bokslutskommuniké 2020
2020-05-14 Extra Bolagsstämma 2020
2020-03-27 Kvartalsrapport 2020-Q3
2019-12-30 Kvartalsrapport 2020-Q2
2019-11-06 Extra Bolagsstämma 2019
2019-09-27 Ordinarie utdelning VIVE 0.00 SEK
2019-09-26 Årsstämma 2020
2019-09-26 Kvartalsrapport 2020-Q1
2019-07-12 Bokslutskommuniké 2019
2019-03-01 Kvartalsrapport 2019-Q3
2018-11-30 Kvartalsrapport 2019-Q2
2018-09-25 Årsstämma 2019
2018-09-05 Ordinarie utdelning VIVE 0.00 SEK
2018-08-31 Kvartalsrapport 2019-Q1
2018-06-08 Bokslutskommuniké 2018
2018-03-02 Kvartalsrapport 2018-Q3
2017-12-01 Kvartalsrapport 2018-Q2
2017-09-26 Ordinarie utdelning VIVE 0.00 SEK
2017-09-25 Årsstämma 2018
2017-09-01 Kvartalsrapport 2018-Q1
2017-06-08 Bokslutskommuniké 2017
2017-03-03 Kvartalsrapport 2017-Q3
2016-12-02 Kvartalsrapport 2017-Q2
2016-11-21 Extra Bolagsstämma 2016
2016-09-27 Ordinarie utdelning VIVE 0.00 SEK
2016-09-26 Årsstämma 2017
2016-09-02 Kvartalsrapport 2017-Q1
2016-06-03 Bokslutskommuniké 2016
2016-03-03 Kvartalsrapport 2016-Q3
2015-12-03 Kvartalsrapport 2016-Q2
2015-09-29 Ordinarie utdelning VIVE 0.00 SEK
2015-09-28 Årsstämma 2016
2015-09-03 Kvartalsrapport 2016-Q1
2015-06-04 Bokslutskommuniké 2015
2015-03-05 Kvartalsrapport 2015-Q3
2014-12-04 Kvartalsrapport 2015-Q2
2014-09-30 Ordinarie utdelning VIVE 0.00 SEK
2014-09-29 Årsstämma 2015
2014-09-05 Kvartalsrapport 2015-Q1
2014-06-05 Bokslutskommuniké 2014
2014-03-06 Kvartalsrapport 2014-Q3
2013-12-05 Kvartalsrapport 2014-Q2
2013-10-01 Ordinarie utdelning VIVE 0.00 SEK
2013-09-06 Kvartalsrapport 2014-Q1
2013-06-07 Bokslutskommuniké 2013
2013-03-13 15-7 2013
2013-03-01 Kvartalsrapport 2012-Q3
2012-12-06 Kvartalsrapport 2012-Q2
2012-09-25 Ordinarie utdelning VIVE 0.00 SEK
2012-09-24 Årsstämma 2012
2012-09-06 Kvartalsrapport 2012-Q1
2012-06-14 Bokslutskommuniké 2011
2012-03-08 Kvartalsrapport 2011-Q3
2011-12-08 Kvartalsrapport 2011-Q2
2011-10-03 Ordinarie utdelning VIVE 0.00 SEK
2011-09-30 Årsstämma 2011
2011-09-08 Kvartalsrapport 2011-Q1
2011-06-10 Bokslutskommuniké 2010
2010-12-09 Kvartalsrapport 2010-Q2
2010-09-24 Årsstämma 2010
2010-09-09 Kvartalsrapport 2010-Q1
2009-12-10 Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Vivesto är ett forskningsbolag. Bolaget är specialiserat inom forskning och utveckling av läkemedel för svåra sjukdomar inom onkologi. Tekniken baseras på bolagets tekniska plattform där forskning sker utifrån nanoteknik. Idag innehas verksamhet främst inom Norden och Nordamerika. Bolaget grundades under 1999 och har idag sitt huvudkontor i Uppsala.
2021-08-26 07:00:00

- Key roles reinforce Oasmia’s capacity to progress and expand its clinical-stage oncology portfolio

Solna, Sweden, August 26, 2021 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, today announces the appointments of Kia Bengtsson as Head of Clinical Development and Johanna Röstin as Head of Regulatory Affairs with effect from October 1, 2021. The appointments significantly strengthen Oasmia’s internal drug development expertise as the company progresses its portfolio of cancer therapies through the clinic and evaluates opportunities to further expand the pipeline through M&A and in-licensing.

Kia Bengtsson commented: “Oasmia is building a strong oncology-focused business, with important international clinical studies underway and clear ambitions to build a broad cancer portfolio. I look forward to joining the company at this exciting time and to supporting its growth strategy.”

Kia Bengtsson was previously Director, Drug Development, at the Swedish nanotechnology company Nanologica, with responsibility for pre-clinical and clinical development. In more than 20 years at leading pharma and biotech companies, Kia has worked on the development of innovative therapies including Somatuline™ for the treatment of neuroendocrine tumors and Decapeptyl™ for the treatment of prostate cancer. She held leading positions in drug development and clinical operations at Ipsen, AstraZeneca and Eurocine Vaccines. Kia began her career as a registered nurse at Karolinska University Hospital.

Johanna Röstin said: “Oasmia is putting in place a first-class in-house team to help it bring new options to patients with ovarian and prostate cancer and to expand its portfolio of innovative products. This is a great opportunity to help build a leading oncology company focused on innovation.”

Johanna Röstin joins Oasmia from OxThera AB, where she is Director of CMC, Program Management and Regulatory. Johanna spent 10 years at Swedish Orphan Biovitrum AB (Sobi), where she was regulatory responsible for one of Sobi’s leading biological products commercialized in the EU and US as Global Senior Regulatory Affairs Manager. She was Regulatory CMC expert for commercial- and development-stage biological products. She has also worked for Pharmacia and Biovitrum. Johanna has an M.Sc in chemical engineering / biotechnology and a Licentiate degree in biotechnology from the KTH Royal Institute of Technology in Stockholm.

Dr Heidi Ramstad, Chief Medical Officer at Oasmia, commented: ’’We are delighted to welcome Kia and Johanna to Oasmia as we enter a new phase of clinical development with our oncology portfolio. We’ll also benefit from their extensive industry experience as we continue to broaden our pipeline and establish Oasmia as a leading, sustainable oncology company focused on bringing new treatment approaches to patients’’.

For More Information: 

Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com

Consilium Strategic Communications 
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has an emerging pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.